Core Viewpoint - In the context of ongoing adjustments in the Hong Kong stock market, Yidu Tech (02158) has demonstrated its intrinsic value and management confidence through a series of solid buyback operations and significantly improved interim performance [1] Buyback Operations - On December 9, Yidu Tech announced a buyback of 345,000 shares at a price of HKD 5.15 per share, amounting to approximately HKD 1.78 million [1] - The company has implemented buybacks for five consecutive trading days, totaling around 1.42 million shares and exceeding HKD 7.3 million in total buyback amount [1] Financial Performance - For the interim results of the fiscal year 2026, Yidu Tech reported total revenue of RMB 358 million, representing a year-on-year growth of 8.7% [1] - The adjusted EBITDA for existing business reached approximately RMB 54 million, doubling compared to the same period last year, with the company nearing breakeven on the accounting level, achieving this milestone about a year ahead of management's original expectations [1] Market and Industry Trends - According to Guosen Securities, the short-term adjustment in the Hong Kong stock market provides space for recovery in 2026 [1] - The US dollar index is expected to weaken in early 2026, benefiting the valuation recovery of emerging markets [1] - The AI sector remains a key focus for 2026, driven by the need for accelerated domestic hardware production and the anticipation of more AI applications [1] AI Medical Sector - Yidu Tech operates in the AI medical sector, which is one of the most barrier-protected and demand-driven core scenarios in the "AI empowering various industries" trend [1] - The company's medical large model technology has entered a new phase of "multiple blooming and large-scale landing," evidenced by three dimensions: 1. Deep application in well-known hospitals, with the AI middle platform implemented in over 30 top-tier hospitals, achieving nearly 1,000 high-frequency calls per day in a single hospital [1] 2. Significant improvement in the accuracy of the TNM staging assessment intelligent agent for key specialties [1] 3. Integration of expert wisdom through the digital twin of doctors, allowing broader service of clinical experience to patients [1]

Core Viewpoint - In the context of ongoing adjustments in the Hong Kong stock market, Yidu Tech (02158) has demonstrated its intrinsic value and management confidence through a series of solid buyback operations and significantly improved interim performance [1] Group 1: Buyback Operations - On December 9, Yidu Tech announced a buyback of 345,000 shares at a price of HKD 5.15 per share, totaling approximately HKD 1.78 million [1] - The company has implemented buybacks for five consecutive trading days, accumulating around 1.42 million shares with a total expenditure exceeding HKD 7.3 million [1] Group 2: Financial Performance - For the interim report of the fiscal year 2026, Yidu Tech reported total revenue of RMB 358 million, representing a year-on-year growth of 8.7% [1] - The adjusted EBITDA for existing business reached approximately RMB 54 million, doubling compared to the same period last year, with the company nearing breakeven on its financial statements, achieving this milestone about a year ahead of management's original expectations [1] Group 3: Market and Industry Trends - According to Guosen Securities, the short-term adjustment in the Hong Kong stock market provides space for recovery in 2026, with the US dollar index expected to weaken in early 2026, benefiting the valuation recovery of emerging markets [1] - The AI sector remains a key focus for 2026, driven by the need for accelerated domestic hardware production and the anticipation of more AI applications, with companies increasingly utilizing AI to enhance labor productivity [1] Group 4: Company Positioning in AI Healthcare - Yidu Tech operates in the AI healthcare sector, which is one of the most barrier-rich and demand-driven core scenarios in the "AI empowering various industries" landscape [1] - The company's medical large model technology has entered a new phase of "multiple blooming and large-scale implementation," evidenced by three dimensions: deep application in over 30 top-tier hospitals, significant accuracy improvements in TNM staging assessment, and the integration of expert clinical experience through digital avatars of doctors [1]

Group 1 - The core viewpoint of the news is that Yidu Technology (2158) is demonstrating strong growth and operational efficiency, as evidenced by its recent share buybacks and positive financial performance [1][2] - The company repurchased 181,000 shares at an average price of HKD 5.15, totaling over HKD 930,000, marking a continuous buyback trend with a cumulative amount nearing HKD 3 million [1] - For the fiscal year 2026, Yidu Technology reported total revenue of RMB 358 million, reflecting an 8.7% year-on-year growth, with adjusted EBITDA reaching approximately RMB 54 million, doubling from the previous year [1] Group 2 - The management highlighted that the AI medical model technology has entered a new phase of "multi-point blossoming and large-scale landing," with significant deployments in over 30 top-tier hospitals [2] - The AI tool "Copilot" is being utilized nearly 1,000 times daily in individual hospitals, integrating into actual workflows [2] - The diagnostic accuracy of the TNM staging assessment tool has improved significantly, with T-stage accuracy rising from 58% to 90%, reaching the level of chief physicians [2] Group 3 - Capital market analysts are optimistic about Yidu Technology, with Everbright Securities noting breakthroughs in AI medical innovation and the establishment of a "data + algorithm + scenario" closed-loop system [2] - Citigroup maintained a "Buy" rating for the company with a target price of HKD 10, recognizing its core competitiveness and growth potential in the AI healthcare sector [2] Group 4 - As of the latest market close, Yidu Technology's stock price was HKD 5.15, reflecting a 0.98% increase [3]

Group 1 - The company repurchased 181,000 shares at an average price of HKD 5.15, totaling over HKD 930,000, marking the second consecutive day of buybacks, with a cumulative total of approximately 573,000 shares and nearly HKD 3 million in total repurchases [1] - Since September 26, the company has completed 12 repurchase transactions, with a cumulative repurchase amount exceeding HKD 25 million [1] - The company reported total revenue of RMB 358 million for the fiscal year 2026, representing a year-on-year growth of 8.7%, with adjusted EBITDA reaching approximately RMB 54 million, doubling from the same period last year [1] Group 2 - The management highlighted that the AI medical model technology has entered a new phase of "multiple blooms and large-scale implementation," evidenced by deep deployment in over 30 top-tier hospitals nationwide [2] - The diagnostic accuracy of the developed TNM staging assessment tool has significantly improved, with T-stage accuracy rising from 58% to 90%, reaching the level of chief physicians [2] - Brokerages are releasing positive signals, with Everbright Securities noting the company's breakthroughs in AI medical innovation and Citigroup maintaining a "buy" rating with a target price of HKD 10, recognizing its core competitiveness and growth potential in the AI healthcare sector [2]

Core Insights - The company, Yidu Tech (2158.HK), reported a healthy revenue growth of 8.7% year-on-year, reaching RMB 358 million for the first half of the 2026 fiscal year [1][4] - The adjusted EBITDA for existing business doubled compared to the same period last year, amounting to approximately RMB 54 million, indicating significant improvement in profitability and operational efficiency [1][7][10] - The company has entered a new phase of its large model technology, with deep applications in over 30 top-tier hospitals and a substantial increase in order amounts across its core segments [1][14] Revenue and Profitability - Total revenue for the reporting period was RMB 358 million, reflecting an 8.7% increase year-on-year [1][4] - Adjusted EBITDA for existing business reached approximately RMB 54 million, showing a significant improvement compared to the previous year [1][7] - The company is nearing breakeven in its financial statements, ahead of management's previous expectations by one year [1][10] Order Growth - The core business segments saw substantial growth in new order amounts, with the big data platform and solutions segment increasing by 19.7% year-on-year, and the life sciences solutions segment experiencing a remarkable 61.1% increase [1][9] Technological Advancements - The company’s large model technology has evolved into a stage of "multiple blooms and large-scale landing," evidenced by its deep application in top hospitals and high-frequency usage of its AI Copilot [1][14][22] - The accuracy of the TNM staging assessment AI has significantly improved, with T staging accuracy reaching 90% and N staging accuracy reaching 80% [1][20][21] Business Collaboration and Ecosystem - The company has established collaborations with top experts and hospitals, creating a digital twin of doctors to extend expert clinical experience to a broader patient base [1][14] - The company has been actively involved in health management, serving over 44 healthcare institutions and covering nearly 30 cities and provinces [1][28]

Core Insights - Yidu Technology reported a total revenue of RMB 358 million for the first half of the 2026 fiscal year, representing an 8.7% year-on-year growth, with adjusted EBITDA doubling to approximately RMB 54 million [1] - The company has seen significant growth in its core business segments, with new order amounts in the big data platform and solutions segment increasing by 19.7% and the life sciences solutions segment by 61.1% [1] - The management highlighted advancements in AI technology, with applications in over 30 top-tier hospitals and a significant increase in the accuracy of its TNM staging assessment tool [1][2] Business Segment Performance - The big data platform and solutions segment generated revenue of RMB 153 million, a 14.6% increase year-on-year, providing solutions to 127 top hospitals and 44 regulatory bodies [3] - The life sciences solutions segment achieved revenue of RMB 138 million, supporting the accelerated approval of several innovative drugs and gaining recognition in real-world research [4] - The health management platform and solutions segment reported revenue of RMB 66.67 million, a 30.3% increase, with significant participation in public health insurance projects and a notable rise in active users [5] Technological Advancements - YiduCore, the company's core algorithm engine, processed over 1.3 billion patient visits and nearly 7 billion authorized medical records, covering over 10,000 hospitals [1] - The company has successfully reduced the incidence of "hallucinations" in AI models to below 1% and improved the accuracy of its TNM staging assessment tool significantly [2] - Yidu Technology received industry recognition at the CHIP 2025 conference, winning awards for its advancements in medical NLP [2]